Date:	Title:
01/10/07	First FDA Approval for FM Treatment Drug Expected by 2008 Pharmaceutical companies are “racing�?to gain regulatory approval for their drugs to serve the virtually untapped Fibromyalgia market, according to an industry update from Reuters news dated January 7.
11/29/06	The Danger in Sleeping Pill Advertising: Reading Beyond the Lines Some American consumers, encouraged by increasingly heavy advertising of prescription sleep drugs, may be assuming unnecessary risk because they're ill informed about the pro's and con's of these "sedative/hypnotics" versus other means of coping with sleep problems. So says the latest in a series of drug comparisons that the independent, nonprofit Consumer Reports organization (CR) has produced as part of a public Drug Effectiveness Review Project.
11/29/06	Major Late-Round Ampligen® Trial Recruits in Seven States An open label Phase III “intervention�?study of the antiviral drug AmpligenR 511 - the most recent step in Hemispherx Biopharma’s decade-long quest for FDA approval - is recruiting subjects with “severely debilitating�?CFS/ME at centers in seven states, nationwide, according to ClinicalTrials.gov.
11/22/06	Major Trial Concludes Pregabalin (Lyrica®) Promising FM Pain Therapy Many FM Patients Report Pain "Much or Very Much Improved" In Lengthy Pregabalin Trial
11/17/06	An FM Pharmacy Treatment Update for Pharmacists, Patients, & Physicians This FM research update, reproduced with permission of U.S. Pharmacist, was developed to help pharmacists counsel FM patients and their physicians about treatment options - and “to recognize patients with FMS-like symptoms who are self-treating�?and may need medical treatment.
11/07/06	Medicare: More Than 600,000 Medicare Prescription Drug Benefit Beneficiaries Must Apply for Low-Income Subsidy for 2007 Medicare: More Than 600,000 Medicare Prescription Drug Benefit Beneficiaries Must Apply for Low-Income Subsidy for 2007
09/18/06	DEA Proposes 90-day Painkiller Prescriptions Currently, physicians prescribing a “Schedule II�?controlled painkiller such as codeine or Oxycontin are required to limit any prescription to a 30-day supply �?technically requiring patients with serious chronic pain to return for repeated office visits. But as of September 5, 2006, the U.S. Drug Enforcement Administration (DEA) proposed a change in the rule that would increase Schedule II prescriptions to 90 days.